AR055677A1 - Combinacion terapeutica que comprende metotrexato - Google Patents

Combinacion terapeutica que comprende metotrexato

Info

Publication number
AR055677A1
AR055677A1 ARP060104391A ARP060104391A AR055677A1 AR 055677 A1 AR055677 A1 AR 055677A1 AR P060104391 A ARP060104391 A AR P060104391A AR P060104391 A ARP060104391 A AR P060104391A AR 055677 A1 AR055677 A1 AR 055677A1
Authority
AR
Argentina
Prior art keywords
metotrexate
therapeutic combination
combination
pteridinyl
phenylamino
Prior art date
Application number
ARP060104391A
Other languages
English (en)
Spanish (es)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR055677A1 publication Critical patent/AR055677A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
ARP060104391A 2005-10-07 2006-10-05 Combinacion terapeutica que comprende metotrexato AR055677A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72454205P 2005-10-07 2005-10-07

Publications (1)

Publication Number Publication Date
AR055677A1 true AR055677A1 (es) 2007-08-29

Family

ID=37943172

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104391A AR055677A1 (es) 2005-10-07 2006-10-05 Combinacion terapeutica que comprende metotrexato

Country Status (3)

Country Link
JP (1) JP2007106762A (fr)
AR (1) AR055677A1 (fr)
WO (1) WO2007042885A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11084780B1 (en) 2021-02-17 2021-08-10 Springworks Therapeutics, Inc. Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11066358B1 (en) 2021-02-17 2021-07-20 Warner-Lambert Company Llc Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11571402B2 (en) 2021-02-17 2023-02-07 Springworks Therapeutics, Inc. Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
WO2023223205A1 (fr) 2022-05-17 2023-11-23 Teva Pharmaceuticals International Gmbh Formes à l'état solide de mirdamétinib et leur procédé de préparation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001273498B2 (en) * 2000-07-19 2006-08-24 Warner-Lambert Company Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
EP1682495A1 (fr) * 2003-10-21 2006-07-26 Warner-Lambert Company LLC Forme polymorphe du i n /i - (r)-2,3-dihydroxy-propoxy|-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide

Also Published As

Publication number Publication date
WO2007042885A3 (fr) 2007-12-06
WO2007042885A2 (fr) 2007-04-19
JP2007106762A (ja) 2007-04-26

Similar Documents

Publication Publication Date Title
CU20000176A7 (es) Composiciones de celecoxib
ES2525497T1 (es) Composición farmacéutica de liberación controlada que comprende éster de ácido fumárico
van Weeren et al. Pain in osteoarthritis
AR055677A1 (es) Combinacion terapeutica que comprende metotrexato
US20220202744A1 (en) Methods of treating mental disorders
Carta et al. The clinical use of gabapentin in bipolar spectrum disorders
BRPI0608205B8 (pt) derivado heterocíclico-1-carboxilato de piridila não-aromático nitrogenado, composição farmacêutica e uso do dito composto para o tratamento de frequência urinária, incontinência urinária, bexiga hiperativa e dor
AR054139A1 (es) Formulacion modificada y de liberacion inmediata de esferas de memantina
AR036943A1 (es) Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil)fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
NO20061662L (no) Farmasoytisk preparat omfattende en P2X7 reseptorantagonisk og ikke-steroid intiinfammatorisk medikament
AR036813A1 (es) Composiciones farmaceuticas
UY27993A1 (es) Derivados de 4-pirrolidino-fenil-bencil eter
UY28400A1 (es) Metabolito
US9155502B2 (en) Treatment of cerebral palsy impaired speech in children
CO6270217A2 (es) Formulaciones galenicas de alisquireno y valsartan
PA8579801A1 (es) Composiciones farmaceuticas de farmacos semiordenados y polimeros
JP2006104186A (ja) 感冒用医薬組成物
AR042543A1 (es) Composiciones de anti-histaminicos, descongestivos y drogas anti-inflamatorias no esteroides
CL2009000980A1 (es) Uso de (s)-n-(2-(1,6,8-tetrahidro-2h-inden[5,4-b]furan-8-il)etil]propionamida en combinacion con una o más drogas seleccionadas de un grupo definido para preparar un medicamento útil para la prevencion o tratamiento de la depresión o desórdenes de ansiedad (divisional de la solicitud 749-2006).
ECSP22081150A (es) Composición farmacéutica para la prevención o tratamiento de enfermedad infecciosa viral de arn epidémica
MXPA05012705A (es) Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis tumoral.
HRP20110139T1 (hr) Farmaceutski pripravak koji ima antipsihotičku, antidepresivnu ili antiepileptičku aktivnost sa smanjenim nuspojavama
Pareek Use of mefenamic acid as a supportive treatment of COVID-19: a repurposing drug
ATE375146T1 (de) Schleimdrogenbasierte lutschtablette gegen entzündliche erkrankungen des mund- und rachenraums
WO2004100939B1 (fr) Combinaison de modafinil analeptique et d'antidepressifs pour traiter la depression

Legal Events

Date Code Title Description
FA Abandonment or withdrawal